Skip to main content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Office of Science and Data Policy (SDP)

The Office of Science and Data Policy is the departmental focal point for policy research, analysis, evaluation, and coordination of department-wide public health science policy and data policy activities and issues. The Office provides authoritative advice and analytical support to the ASPE and departmental leadership on public health science policy and data policy issues and initiatives, coordinates science and data policy issues of interagency scope within HHS, and manages interagency initiatives in science policy and data policy. The Office works closely with staff from across the Department on strategic plan development and implementation efforts. The Offices also carries out a program of policy research, analysis, evaluation, and data development in these issues.

The Office of Science and Data Policy includes several components:

Topic Areas:

  • HHS Data Council
  • Regulatory Impact Analysis
  • Strategic Planning
  • Information Quality Guidelines
  • Prevention and wellness
  • Public health systems and functions
  • Food safety and nutrition
  • Drugs and devices
  • Tobacco control and prevention
  • Biomedical research and development
  • Economic analysis
  • Emergency preparedness, response, and recovery
  • Data and statistical policy
  • Health disparities and vulnerable populations
  • Health information technology
  • Microsimulation
  • Privacy policy

Reports

Displaying 11 - 20 of 156. 10 per page. Page 2.

Advanced Search
Fact Sheet, Report

Inflation Reduction Act Research Series: Understanding Development and Trends in Utilization and Spending for Drugs Selected Under the Medicare Drug Price Negotiation Program

The Inflation Reduction Act (IRA) authorizes the Secretary of the Department of Health and Human Services (HHS) to negotiate prices directly with participating manufacturers for selected drugs that are high expenditure, single source drugs without generic or biosimilar competition.
Report

Analysis of Market Challenges for Antimicrobial Drug Development in the United States

The market for antimicrobial (AM) drugs is unique in that it is associated with a positive externality (public health) as well as a negative externality (antimicrobial resistance, or AMR) (Mossialos, et al., 2010). AMR occurs when microbes change over time and no longer respond to available medicine.
Report

Antimicrobial Drugs - Burden of Antimicrobial Resistance

It is well known that antimicrobial resistance (AMR) creates a substantial and ongoing public health and economic burden and understanding the size and nature of this burden is important for the ability to respond to the threat of AMR. However, estimating or projecting that burden within the U.S.
Report

Antimicrobial Drugs - Market Returns Analysis

In 2017, at least 2.8 million people in the U.S. acquired serious infections with bacteria that are resistant to one or more antimicrobial drugs and 35,000 have died as a result. Resistance to antimicrobials is viewed as a global threat with antimicrobial drug use in human and animal health driving resistance.
Report

National Action Plan for Combating Antibiotic-Resistant Bacteria Progress Report: Fiscal Year 2021

Pathogens that have evolved to be resistant to the drugs currently used to treat infections are an ongoing threat to public health, animal health, food production, and national security. Globally, a recent analysis estimated that 1.2 million deaths were caused by antibiotic-resistant (AR) bacteria in 2019, making this threat a leading cause of death for people of all ages worldwide.
Report to Congress

ASPE Report to Congress: Impact of Drug Shortages on Consumer Costs

Prescription drug shortages are an ongoing concern in the United States (U.S.). While prior analyses explore the frequency of drug shortages in the U.S., little is known about the extent to which U.S. shortages impact consumer costs and healthcare systems. Drug shortages impact consumer costs in various ways.
Report

Understanding Coverage Considerations for COVID-19 Vaccines and Treatments

Understanding Coverage Considerations for COVID-19 Vaccines and Treatments (Updated May 2023)
Research Summary

Optimizing Clinical Guidelines to Address Antimicrobial-Resistant Infections: A Conceptual Framework Reflecting Stakeholder Perspectives

Objectives: Clinical guidelines or guidance is an important tool for preventing and treating antimicrobial-resistant (AMR) infections. We sought to understand and support the effective use of guidelines and guidance for AMR infections.
ASPE Issue Brief

FDA User Fees: Examining Changes in Medical Product Development and Economic Benefits

This issue brief provides a primer on FDA user fees, presents findings of how user fees affect the cost of medical product development, and summarizes the research literature on user fees, most notably in expediting medical product development and approval.
ASPE Issue Brief

COVID-19 Vaccine Hesitancy and Reasons for Hesitancy Among Essential and Non-Essential Workers

Using 2021-2022 survey data from the U.S. Census Bureau’s Household Pulse Survey, this ASPE Research Report examined sociodemographic factors and trends in vaccine hesitancy among workers based on the likelihood of exposure risk to SARS-CoV-2. We classified work setting into three categories: essential healthcare, essential non-healthcare, and non-essential.